156 research outputs found
Faits marquants de la production bovine en Australie
Australia has developed for about 20 years the Meat Standards Australia (MSA) grading scheme to predict beef eating quality and hence better satisfy beef consumers. More than 3.1 million cattle were processed through MSA pathways in 2017-18. The cattle presented for MSA grading accounted for 43% of the national adult cattle slaughter and 94.3% of cattle presented for grading met MSA minimum requirements. The Meat Livestock Australia has also developed the MSA index, which indicates an eating quality potential at the whole carcass level. Since 2011, the average MSA Index has increased by roughly 1.5% from 2010-11 to 2016-17 to reach 57.78 in 2017-18. More than 5,000 meat producers became registered to supply livestock through the MSAprogram, and the average price differential between MSA and non-MSA carcasses from young cattle across all weight ranges (excluding accredited grainfed cattle) was 0.13/kg for cattle that met grainfed accreditation standards). Thus, in the last year, it is estimated that the MSA program delivered an additional AUD / kg (et de 0,13 $ / kg pour les bovins alimentés avec des concentrés). Ainsi, au cours de la dernière année, on estime que le programme MSA a généré une plus-value de 152 millions de dollars australiens pour les producteurs de viande bovine australienne
Effects of Human Alpha-Synuclein A53T-A30P Mutations on SVZ and Local Olfactory Bulb Cell Proliferation in a Transgenic Rat Model of Parkinson Disease
A transgenic Sprague Dawley rat bearing the A30P and A53T α-synuclein (α-syn) human mutations under the control of the tyrosine hydroxylase promoter was generated in order to get a better understanding of the role of the human α-syn mutations on the neuropathological events involved in the progression of the Parkinson's disease (PD). This rat displayed olfactory deficits in the absence of motor impairments as observed in most early PD cases. In order to investigate the role of the mutated α-syn on cell proliferation, we focused on the subventricular zone (SVZ) and the olfactory bulbs (OB) as a change of the proliferation could affect OB function. The effect on OB dopaminergic innervation was investigated. The human α-syn co-localized in TH-positive OB neurons. No human α-syn was visualized in the SVZ. A significant increase in resident cell proliferation in the glomerular but not in the granular layers of the OB and in the SVZ was observed. TH innervation was significantly increased within the glomerular layer without an increase in the size of the glomeruli. Our rat could be a good model to investigate the role of human mutated α-syn on the development of olfactory deficits
Substantially improved pharmacokinetics of recombinant human butyrylcholinesterase by fusion to human serum albumin
<p>Abstract</p> <p>Background</p> <p>Human butyrylcholinesterase (huBChE) has been shown to be an effective antidote against multiple LD<sub>50 </sub>of organophosphorus compounds. A prerequisite for such use of huBChE is a prolonged circulatory half-life. This study was undertaken to produce recombinant huBChE fused to human serum albumin (hSA) and characterize the fusion protein.</p> <p>Results</p> <p>Secretion level of the fusion protein produced <it>in vitro </it>in BHK cells was ~30 mg/liter. Transgenic mice and goats generated with the fusion constructs expressed in their milk a bioactive protein at concentrations of 0.04–1.1 g/liter. BChE activity gel staining and a size exclusion chromatography (SEC)-HPLC revealed that the fusion protein consisted of predominant dimers and some monomers. The protein was confirmed to have expected molecular mass of ~150 kDa by Western blot. The purified fusion protein produced <it>in vitro </it>was injected intravenously into juvenile pigs for pharmacokinetic study. Analysis of a series of blood samples using the Ellman assay revealed a substantial enhancement of the plasma half-life of the fusion protein (~32 h) when compared with a transgenically produced huBChE preparation containing >70% tetramer (~3 h). <it>In vitro </it>nerve agent binding and inhibition experiments indicated that the fusion protein in the milk of transgenic mice had similar inhibition characteristics compared to human plasma BChE against the nerve agents tested.</p> <p>Conclusion</p> <p>Both the pharmacokinetic study and the <it>in vitro </it>nerve agent binding and inhibition assay suggested that a fusion protein retaining both properties of huBChE and hSA is produced <it>in vitro </it>and <it>in vivo</it>. The production of the fusion protein in the milk of transgenic goats provided further evidence that sufficient quantities of BChE/hSA can be produced to serve as a cost-effective and reliable source of BChE for prophylaxis and post-exposure treatment.</p
Prevalence and factors associated with alcohol and drug-related disorders in prison: a French national study
BACKGROUND: Most studies measuring substance-use disorders in prisons focus on incoming or on remand prisoners and are generally restricted to drugs. However, there is evidence that substance use initiation or continuation occurs in prison, and that alcohol use is common. The aim of this study is 1) to assess prevalence of both drug and alcohol abuse and dependence (DAD/AAD) in a national randomised cohort of French prisoners, short or long-term sentence 2) to assess the risk factors associated with DAD/AAD in prison. a stratified random strategy was used to select 1) 23 prisons among the different types of prison 2) 998 prisoners. Diagnoses were assessed according to a standardized procedure, each prisoner being assessed by two psychiatrists, one junior, using a structured interview (MINI 5 plus), and one senior, completing the procedure with an open clinical interview. At the end of the interview the clinicians met and agreed on a list of diagnoses. Cloninger's Temperament and Character Inventory (TCI) was also used. RESULTS: More than a third of prisoners presented either AAD or DAD in the last 12 months. Cannabis was the most frequent drug and just under a fifth of prisoners had AAD. AAD and DAD were clearly different for the following: socio-demographic variables, childhood history, imprisonment characteristics, psychiatric comorbidity and Cloninger's TCI. Profiles of AAD in prison are similar to type II alcoholism. CONCLUSION: Regular screening of AAD/DAD in prison, and specific treatment programmes taking into account differences between prisoners with an AAD and prisoners with a DAD should be a public health priority in priso
Dix ans d'histoire culturelle
L'association pour le développement de l'histoire culturelle (ADHC) est née, en 1999, du constat de la place croissante, en même temps que problématique, de l'histoire culturelle dans l'historiographie contemporaine. Revendiquée par les uns, dénoncée par les autres, cette place méritait l'institution d'un lieu de rencontres où tous ceux qui se reconnaissent dans cette qualification pourraient échanger sur le fond et sur la forme de leur travail. L'association a tenu son premier congrès en 2000. Au terme d'une décennie et plus d'activité, il était temps de tirer le bilan et, comme il se doit, de tracer de nouvelles perspectives. Cette anthologie des conférences et tables rondes organisées dans le cadre du congrès annuel de l'association propose un panorama unique en son genre des propositions avancées par l'histoire culturelle en France et, dans une moindre mesure, à l'étranger depuis dix ans. Regroupés en sections thématiques (définitions et frontières, objets, regards et transferts, débats), ces textes rédigés par d'éminents spécialistes venus de divers horizons (historiens, sociologues, philosophes, historiens de l'art ou de la littérature) donnent à voir à la fois la permanence de certains questionnements et leur renouvellement
- …
